ArticleGene therapy2011
Molecular adjuvant HMGB1 enhances anti-influenza immunity during DNA vaccination.
Article in Gene therapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 53 citations in OpenAlex.
- Genetic adjuvants: A paradigm shift in vaccine development and immune modulation.Molecular therapy. Nucleic acids · 2025Review
- Advances in Chicken Infectious Anemia Vaccines.Vaccines · 2025Review
- Article
- Photothermal treatment-based heat stress regulates function of myeloid-derived suppressor cells.Scientific reports · 2024Article
- The Dual Role of the Innate Immune System in the Effectiveness of mRNA Therapeutics.International journal of molecular sciences · 2023Review
- Review
- Peptide Aggregation Induced Immunogenic Rupture (PAIIR).Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Self-adjuvanting nanovaccines boost lung-resident CD4NPJ vaccines · 2022Article
- Using PAMPs and DAMPs as adjuvants in cancer vaccines.Human vaccines & immunotherapeutics · 2021Review
- Role of Damage-Associated Molecular Pattern/Cell Death Pathways in Vaccine-Induced Immunity.Viruses · 2021Review
- Non-thermal plasma modulates cellular markers associated with immunogenicity in a model of latent HIV-1 infection.PloS one · 2021Article
- Beneficial effect of Indigo Naturalis on acute lung injury induced by influenza A virus.Chinese medicine · 2020Article
- Adjuvant Screen Identifies Synthetic DNA-Encoding Flt3L and CD80 Immunotherapeutics as Candidates for Enhancing Anti-tumor T Cell Responses.Frontiers in immunology · 2020Article
- Immunogenicity and Toxicity of Different Adjuvants Can Be Characterized by Profiling Lung Biomarker Genes After Nasal Immunization.Frontiers in immunology · 2020Article
- The proinflammatory protein HMGB1 is a substrate of transglutaminase-2 and forms high-molecular weight complexes with autoantigens.The Journal of biological chemistry · 2018Article
- Article
- A Review of DNA Vaccines Against Influenza.Frontiers in immunology · 2018Review
- An optimized HMGB1 expressed by recombinant rabies virus enhances immunogenicity through activation of dendritic cells in mice.Oncotarget · 2017Article
- Elevated HMGB1-related interleukin-6 is associated with dynamic responses of monocytes in patients with active pulmonary tuberculosis.International journal of clinical and experimental pathology · 2015Article
- Novel and enhanced anti-melanoma DNA vaccine targeting the tyrosinase protein inhibits myeloid-derived suppressor cells and tumor growth in a syngeneic prophylactic and therapeutic murine model.Cancer gene therapy · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
Abstract
DNA-based vaccines, while highly immunogenic in mice, generate significantly weaker responses in primates. Therefore, current efforts are aimed at increasing their immunogenicity, which include optimizing the plasmid/gene, the vaccine formulation and method of delivery. For example, co-immunization with molecular adjuvants encoding an immunomodulatory protein has been shown to improve the antigen (Ag)-specific immune response. Thus, the incorporation of enhancing elements, such as these, may be particularly important in the influenza model in which high titered antibody (Ab) responses are critical for protection. In this regard, we compared the ability of plasmid-encoded high-mobility group box 1 protein (HMGB1), a novel cytokine in which we have previously mutated in order to increase DNA vaccine immunogenicity, with boost Ag-specific immune responses during DNA vaccination with influenza A/PR/8/34 nucleoprotein or the hemagglutinin of A novel H1N1/09. We show that the HMGB1 adjuvant is capable of enhancing adaptive effector and memory immune responses. Although Ag-specific antibodies were detected in all vaccinated animals, a greater neutralizing Ab response was associated with the HMGB1 adjuvant. Furthermore, these responses improved CD8 T+-cell effector and memory responses and provided protection against a lethal mucosal influenza A/PR/8/34 challenge. Thus, co-immunization with HMGB1 has strong in vivo adjuvant activity during the development of immunity against plasmid-encoded Ag.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.